These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1838285)

  • 1. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L; De Clerck F; Somers Y; Leysen JE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
    Dorn GW; Burch RM; Kochel PJ; Mais DE; Halushka PV
    Biochem Pharmacol; 1987 Jun; 36(12):1913-7. PubMed ID: 2954555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
    Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H
    J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
    Turini ME; Holub BJ
    Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective modulation of the human platelet thromboxane A2/prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solubilized platelet membranes.
    Parent CA; Lagarde M; Venton DL; Le Breton GC
    J Biol Chem; 1992 Apr; 267(10):6541-7. PubMed ID: 1532390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
    Hanasaki K; Arita H
    Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.